A meta-analysis to investigate the role of CRP/Alb ratio in gynecological cancers by Fang et al. confirmed that a high pretreatment CRP/Alb ratio correlated with poor overall and progression-free survival and stage III-IV disease [19]. This evidence concerns the gene CRP and female reproductive organ cancer.